-
Mashup Score: 0
Shawn Dason, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, talks on the role of cytoreductive nephrectomy and metastasectomy in renal cell carcinoma (RCC). The use of cytoreductive nephrectomy has evolved with the availability of better systemic therapies, and patient and disease factors should be considered when determining its suitability. Systemic therapy followed by deferred cytoreductive nephrectomy is an option supported by recent randomized data. Metastasectomy is also approached on an individual basis, considering factors such as solitary site involvement, limited morbidity, and a lower likelihood of quick recurrence. Palliative reasons and alternative treatments like stereotactic body radiotherapy (SBRT) are also discussed in the context of metastasectomy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by co
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the future of erdafitinib in the treatment landscape for metastatic urothelial carcinoma. Frontline treatments for metastatic urothelial carcinoma remain an unmet need, where approximately half of patients are not eligible for the standard of care. Findings from the Phase III THOR trial (NCT03390504) confirmed the promising benefits of erdafitinib, and additional studies will compare the drug to existing therapies such as gemcitabine with carboplatin, or enfortumab vedotin plus pembrolizumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥Arlene O. Siefker-Radtke, MD, of @MDAndersonNews discusses erdafitinib's potential in metastatic urothelial carcinoma treatment, addressing unmet needs and ongoing trials: ➡️https://t.co/IdwkDSG632⬅️ #ASCO23 #Blcsm #UroOnc #UroSoMe
-
-
Mashup Score: 2Robotic Bladder Auto-transplantation in a Heart-beating Brain-dead Human Research Donor - 9 month(s) ago
Human urinary bladder transplantation (BT) has not yet been successfully performed. Analogous organs, such as the uterus, have been transplanted, with a subsequent live birth reported [1]. The current gold standard for bladder replacement involves urinary diversion using a vascularized segment of bowel. Incorporation of bowel into the urinary tract inherently exposes patients to a variety of early and late metabolic, infectious, and renal functional consequences that can be severe, especially in immunosuppressed patients [2–5].
Source: www.europeanurology.comCategories: Latest Headlines, UrologyTweet-
Articles in Press: Robotic Bladder Auto-transplantation in a Heart-beating Brain-dead Human Research Donor https://t.co/aCH5MUlLOB @uro_nima @Cacciamani_MD #Medtwitter #UroSoMe https://t.co/zeMuf16pbm
-
-
Mashup Score: 0Integrating patients’ experiences in bladder cancer therapeutic decisions: challenges and solutions - 9 month(s) ago
Benjamin Garmezy, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the challenges in effectively integrating patients’ experiences into therapeutic decisions in bladder cancer and how these can be addressed. One key challenge is the limited time available for discussions between healthcare professionals and patients, which can hinder the comprehensive exploration of patient perspectives. Additionally, the complexity of medical information and terminology may impede effective communication. To address these challenges, healthcare professionals can allocate sufficient time for discussions, employ patient-friendly language, and utilize decision aids or support tools. Moreover, fostering a culture of shared decision-making and actively involving patients in treatment planning can ensure that their voices are adequately represented and their preferences are considered. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago,
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@BGarmezy (@SarahCannonDocs) discusses challenges in integrating patient experiences into bladder cancer therapeutic decisions and solutions. Time allocation, patient-friendly language, and decision aids are key: ➡️https://t.co/9ioNxvAWAw⬅️ #ASCO23 #BlcSM #UroOnc #UroSoMe
-
-
Mashup Score: 0
Tian Zhang, MD, UT Southwestern Medical Center, Dallas, TX, discusses findings from the Phase II STARTAR trial (NCT03311555) of androgen receptor inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy followed by docetaxel in patients with PSA recurrent prostate cancer. 3-year progression-free survival was increased after treatment, demonstrating the clinical feasibility of intensifying systemic treatments for PSA recurrent prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@TiansterZhang of @utsw highlights Phase II STARTAR trial results, showing improved 3-year PFS in PSA recurrent prostate cancer with intensified treatment: ➡️https://t.co/3ef6cSGqvv⬅️ #ASCO23 #PCSM #UroOnc #UroSoMe #CTSM #TrialUpdate
-
-
Mashup Score: 0Targeted radionuclide therapy in prostate cancer - 9 month(s) ago
Prostate cancer stands as the most frequently detected malignant condition among men, ranking as the second primary contributor to cancer-linked…
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎧In this podcast, we hear from @CalaisJeremie (@UofCalifornia), @DrScottTagawa (@WeillCornell)& @SandhuShahneen (@PeterMacCC) as they share insights and updates in radionuclide therapy for prostate cancer: Listen here➡️https://t.co/B0SJvj9Zvz⬅️ #PCsm #UroOnc #UroSoMe https://t.co/CglHPv5MeY
-
-
Mashup Score: 1STARTAR: AR inhibition + ADT + apalutamide + RT + docetaxel for salvage in PSA recurrent PC after RP - 9 month(s) ago
Andrew J. Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, the primary analysis of the Phase II STARTAR (NCT03311555) salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP). The primary endpoint was 36-month progression-free survival (PFS). Results from the trial demonstrated that the 36-month PFS rate was 72%, with durable remissions beyond historical controls. Most patients completed the planned treatment, achieved undetectable PSA levels, and experienced manageable adverse events. This study suggests that intensifying systemic treatments in the non-metastatic hormone-sensitive but high-risk salvage setting may be feasible and effective in reducing cancer progression. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are ow
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@AarmstrongDuke of @DukeCancer presents STARTAR trial findings! Apalutamide and RT followed by docetaxel show promising 36-month PFS rates of 72% in recurrent prostate cancer after radical prostatectomy: ➡️https://t.co/BMqvcZ7QJ6⬅️ #ASCO23 #PCSM #UroOnc #UroSoMe
-
-
Mashup Score: 12Guidelines for Reporting Observational Research in Urology: The Importance of Clear Reference to Causality - 9 month(s) ago
Observational studies often dance around the issue of causality. We propose guidelines to ensure that papers refer to whether or not the study aim is to investigate causality, and suggest language to use and language to avoid.
Source: www.europeanurology.comCategories: Latest Headlines, UrologyTweet-
Guidelines for Reporting Observational Research in Urology: The Importance of Clear Reference to Causality https://t.co/QjEkbdy8b9 @VickersBiostats @redunndant @zabormetrics @MaartenvSmeden @statsepi #UroSoMe
-
-
Mashup Score: 2
Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, describes the rationale and trial design of the EV-103 trial (NCT03288545), which assessed enfortumab vedotin (EV), an antibody-drug conjugate (ACD), and pembrolizumab in patients with first-line cisplatin-ineligible locally advanced or metastatic urothelial carcinoma. The combination of EV and pembrolizumab had encouraging antitumor activity and a manageable safety profile in cohort A, which had a dose escalation component, and cohort K. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@shilpaonc (@ClevelandClinic) highlights promising results from the EV-103 trial, evaluating enfortumab vedotin and pembrolizumab in cisplatin-ineligible urothelial carcinoma patients: ➡️https://t.co/9XKxFWuy8L⬅️ #ASCO23 #UroOnc #UroSoMe
-
-
Mashup Score: 0Advancements in systemic therapy for kidney cancer: implications for treatment decision-making - 10 month(s) ago
Shawn Dason, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, highlights the significant advancements in systemic therapy for kidney cancer in recent years, leading to improved outcomes compared to the past. While surgical approaches like nephrectomy and metastasectomy haven’t seen major breakthroughs, it’s essential to recognize the changing landscape and consider the latest data when making treatment decisions. Late-breaking abstracts of Phase III trials have shown promising long-term efficacy with systemic therapies. Dr Dason emphasizes the incorporation of the evolving knowledge of systemic treatments into the overall management of kidney cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@shawndason of @OSUCCC_James highlights advancements in systemic therapy for kidney cancer, improving outcomes. Incorporating evolving knowledge is essential in treatment decisions.: ➡️https://t.co/2nwK7ZiOnn⬅️ #ASCO23 #KCSM #UroOnc #UroSoMe
-
🎥@shawndason of @OSUCCC_James discusses the evolving role of cytoreductive nephrectomy & metastasectomy in RCC. Patient factors, systemic therapies, & individualized approaches play a key role: ➡️https://t.co/oSb2DSYHD8⬅️ #ASC023 #kcsm #UroOnc #UroSoMe